GLS-1200 Topical Nasal Spray to Prevent SARS-CoV-2 Infection (COVID-19)

Stopped early · Phase 2 · Has a placebo group

Conditions studied: SARS-CoV 2, Infection

In brief

This clinical trial will evaluate the safety, tolerability and effectiveness of topical GLS-1200 nasal spray to reduce the incidence of confirmed, symptomatic SARS-CoV-2 infection.

Key facts

Study ID

NCT04408183

Run by

GeneOne Life Science, Inc.

People needed

184

Starts

2020-06-10

Expected to finish

2023-01-10

Last updated by the study team

2025-07-31

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Age 18 or older
• Able to provide informed consent
• Able and willing to comply with study procedures
• Able and willing to utilize an approved form of pregnancy prevention for women of child bearing potential through to the end of treatment

You may not qualify if…

• Know allergy to quinine, quinidine, or mefloquine
• Confirmed prior positive test for SARS-CoV-2
• Treatment within the past 2 weeks with chloroquine, hydroxychloroquine, or remdesivir
• Pregnancy or documentation of pregnancy by pre-treatment urine test or breast feeding or plans to become pregnant during the course of the study

Where it is running

• Sinus and Nasal Specialists of Louisiana — Baton Rouge, Louisiana, United States
• University of Pennsylvania — Philadelphia, Pennsylvania, United States
• Conroe Willis Medical Reasearch — Conroe, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.